Answers are grounded in this paper and cite their sources.
Randomized trial tests the effectiveness of added abemaciclib on outcomes in relapsed Ewing sarcoma, suggesting limited benefit.
Introduction: Ewing sarcoma (EWS) is a malignant tumor of primarily bone and soft tissue in children and young adults.The CDK4/6 pathway has emerged as a potential therapeutic target in EWS.Irinotecan and temozolomide are commonly used treatments for relapsed/refractory (R/R) EWS.This Phase 2 study evaluated the potential benefit of adding abemaciclib, a CDK4/6 inhibitor, to irinotecan and temozolomide to treat R/R EWS. Methods:Patients aged 1 to <40 years with R/R EWS were randomized 2:1 to receive abemaciclib plus irinotecan and temozolomide (Arm A) or irinotecan and temozolomide (Arm B).The primary endpoint was progression-free survival (PFS) assessed by a blinded independent review committee (BIRC).Secondary endpoints included PFS by investigator assessment, overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, and pharmacokinetics (PK).Results: Forty-six patients were enrolled (median of two prior lines of therapy).The median PFS by BIRC was 2.8 (Arm A) and 2.9 (Arm B) months.The hazard ratio corresponding to PFS by BIRC was 0.64 (95% confidence interval: 0.28-1.45;nominal p-value = 0.28).ORR was 18.8% (Arm A) and 30.8% (Arm B), and DCR was 56.3% (Arm A) and 53.8% (Arm B).Safety profiles were consistent with the known toxicities of the individual agents; however, the abemaciclib arm showed a higher incidence of high-grade adverse events and required more dose modifications of irinotecan and temozolomide.Conclusions: Abemaciclib did not meaningfully improve PFS when added to irinotecan and temozolomide in R/R EWS.Further exploration of alternative strategies is warranted.
No takes yet. Share an insight, caveat, or question.
Rubio-San-Simon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: